Palvella Therapeutics (PVLA) Income from Continuing Operations (2016 - 2024)
Historic Income from Continuing Operations for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' Income from Continuing Operations fell 12854.56% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 7402.68%. This contributed to the annual value of -$17.4 million for FY2024, which is 19327.48% down from last year.
- Per Palvella Therapeutics' latest filing, its Income from Continuing Operations stood at -$4.0 million for Q4 2024, which was down 12854.56% from -$6.8 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Income from Continuing Operations ranged from a high of $13.8 million in Q4 2023 and a low of -$19.0 million during Q3 2021
- In the last 5 years, Palvella Therapeutics' Income from Continuing Operations had a median value of -$9.2 million in 2021 and averaged -$7.8 million.
- Per our database at Business Quant, Palvella Therapeutics' Income from Continuing Operations crashed by 150869.0% in 2020 and then soared by 22393.45% in 2023.
- Over the past 5 years, Palvella Therapeutics' Income from Continuing Operations (Quarter) stood at -$12.4 million in 2020, then increased by 11.27% to -$11.0 million in 2021, then dropped by 1.48% to -$11.2 million in 2022, then skyrocketed by 223.93% to $13.8 million in 2023, then tumbled by 128.55% to -$4.0 million in 2024.
- Its Income from Continuing Operations was -$4.0 million in Q4 2024, compared to -$6.8 million in Q3 2024 and -$4.2 million in Q2 2024.